Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study on GUselkumab: Effectiveness and Impact on quaLity of LIfe in naïVE or Bio Experienced Patients With Regional (Facial and Genital) Psoriasis (GULLIVER Study)

NCT04439526 is registered in ClinicalTrials.gov with Janssen-Cilag S.p.A. as lead sponsor.

NCT NCT04439526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04439526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study on GUselkumab: Effectiveness and Impact on quaLity of LIfe in naïVE or Bio Experienced Patients With Regional (Facial and Genital) Psoriasis (GULLIVER Study)
Lead sponsor
Janssen-Cilag S.p.A.
Phase
Observational
Overall status
Completed
Start date
June 10, 2020
Completion date
November 21, 2023
Enrollment
356 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis